Prognostic Role of Endoscopic Ultrasound Guided Direct Portal Pressure Gradient Measurement in Porto-Sinusoidal...

HVPG is the gold standard for the diagnosis of clinically significant portal hypertension (CSPH), a condition associated with the risk of developing hepatic decompensation events. However, HVPG is an indirect method to measure portal pressure, and its application in the pre-sinusoidal form of portal hypertension (PH), as in porto-sinusoidal vascular disorder (PSVD), is hindered by low accuracy. Recently, endoscopic ultrasound-guided portal pressure gradient (EUS-PPG) measurement, which allows direct measurement of portal pressure, is emerging as a safe method and may overcome the limitation of HVPG. However, data in patients with CSPH and the pre-sinusoidal form of PH are still missing. This study aims to evaluate the safety and usefulness of EUS-PPG compared to HVPG in a cohort of patients with PSVD and CSPH.

In this prospective single center study, patients with a diagnosis of PSVD who presented a clinical suspicion of CSPH underwent HVPG and EUS-PPG baseline measurements. A second EUS-PPG measurement was performed in patients naïve to non-selective beta-blockers (NSBBs) to evaluate haemodynamic response to therapy.

Twenty-six patients were enrolled and a total of 26 HVPG and 35 EUS-PPG measurements were performed, without any adverse events. Mean EUS-PPG was significantly higher than mean HVPG value (16.7 ± 5.5 mmHg versus 5.5 ± 2.8 mmHg). At logistic multivariate regression analysis, EUS-PPG value was the only variable associated with hepatic decompensation.

EUS-PPG measurement is safe and might have a prognostic role in patients with PSVD and CSPH, outperforming HVPG.

ID5486.